Annaliesa S Anderson

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. pmc Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection
    Annaliesa S Anderson
    Pfizer Vaccine Research and Development, Pearl River, New York, USA
    MBio 7:e00225. 2016
  2. pmc Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus
    Jasdeep S Nanra
    Pfizer Vaccine Research Pearl River, NY USA
    Hum Vaccin Immunother 9:480-7. 2013
  3. pmc Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease
    Annaliesa S Anderson
    Pfizer Vaccine Research Pearl River, NY USA
    Hum Vaccin Immunother 9:471-9. 2013
  4. pmc Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis
    Annaliesa S Anderson
    Pfizer Vaccine Research, Pearl River, NY, USA
    J Infect Dis 205:1688-96. 2012
  5. doi request reprint New frontiers in meningococcal vaccines
    Annaliesa S Anderson
    Pfizer Vaccine Research, Pearl River, NY 10965, USA
    Expert Rev Vaccines 10:617-34. 2011
  6. pmc Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease
    Shannon L Harris
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:68-74. 2011
  7. doi request reprint Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
    Han Qing Jiang
    Pfizer Vaccine Research, 401N Middletown Rd, Pearl River, NY 10965, USA
    Vaccine 28:6086-93. 2010
  8. pmc Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections
    C Hal Jones
    Pfizer Vaccine Research and Development, Pearl River, New York, USA
    J Clin Microbiol 54:25-34. 2016
  9. pmc Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease
    Lisa K McNeil
    Pfizer Vaccine Research, Pearl River, New York, USA
    Microbiol Mol Biol Rev 77:234-52. 2013
  10. doi request reprint Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design
    Jasdeep S Nanra
    Wyeth Vaccine Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 27:3276-80. 2009

Collaborators

Detail Information

Publications28

  1. pmc Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection
    Annaliesa S Anderson
    Pfizer Vaccine Research and Development, Pearl River, New York, USA
    MBio 7:e00225. 2016
    ....
  2. pmc Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus
    Jasdeep S Nanra
    Pfizer Vaccine Research Pearl River, NY USA
    Hum Vaccin Immunother 9:480-7. 2013
    ..This highlights the role of CP as an important immune evasion mechanism and supports the inclusion of capsular polysaccharide antigens in the formulation of multi-component prophylactic vaccines against S. aureus. ..
  3. pmc Potential impact of the bivalent rLP2806 vaccine on Neisseria meningitidis carriage and invasive serogroup B disease
    Annaliesa S Anderson
    Pfizer Vaccine Research Pearl River, NY USA
    Hum Vaccin Immunother 9:471-9. 2013
    ..This suggests that the bivalent fHBP vaccine has the potential to provide protection against invasive MnB strains and interrupt meningococcal carriage, which may also reduce infant MnB disease. ..
  4. pmc Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis
    Annaliesa S Anderson
    Pfizer Vaccine Research, Pearl River, NY, USA
    J Infect Dis 205:1688-96. 2012
    ..This is the first description of a protein that has the potential to provide protection across the staphylococcal species group...
  5. doi request reprint New frontiers in meningococcal vaccines
    Annaliesa S Anderson
    Pfizer Vaccine Research, Pearl River, NY 10965, USA
    Expert Rev Vaccines 10:617-34. 2011
    ..As these challenges are met, the possibility for removing the fear of meningococcal disease from all societies is now becoming a reality...
  6. pmc Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease
    Shannon L Harris
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:68-74. 2011
    ..These promising findings suggest that a bivalent fHBP vaccine may be capable of providing protection against meningococcal disease caused by both serogroup C and B...
  7. doi request reprint Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
    Han Qing Jiang
    Pfizer Vaccine Research, 401N Middletown Rd, Pearl River, NY 10965, USA
    Vaccine 28:6086-93. 2010
    ..Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed...
  8. pmc Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections
    C Hal Jones
    Pfizer Vaccine Research and Development, Pearl River, New York, USA
    J Clin Microbiol 54:25-34. 2016
    ..Based on our findings, WGS is the most suitable approach for the characterization of meningococcal carriage isolates. ..
  9. pmc Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease
    Lisa K McNeil
    Pfizer Vaccine Research, Pearl River, New York, USA
    Microbiol Mol Biol Rev 77:234-52. 2013
    ..This report reviews our current knowledge of fHBP. In particular, we discuss the recent advances in our understanding of fHBP, its importance to N. meningitidis, and its potential role as a vaccine for preventing MnB disease...
  10. doi request reprint Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design
    Jasdeep S Nanra
    Wyeth Vaccine Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 27:3276-80. 2009
    ..The data presented in this report support a multiantigen approach for the development of a prophylactic S. aureus vaccine to ensure broad coverage against this versatile pathogen...
  11. ncbi request reprint Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity
    Ellen Murphy
    Pfizer Vaccine Research, Pearl River, NY, USA
    Hum Vaccin 7:51-9. 2011
    ..Our study also revealed evidence for the de-evolution of ClfB and therefore its reduced suitability as a target for vaccine development compared to ClfA...
  12. pmc A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure
    Julio Hawkins
    Pfizer Vaccine Research, Pearl River, New York, USA
    Clin Vaccine Immunol 19:1641-50. 2012
    ..These functional antibodies were also able to displace S. aureus already bound to Fg, suggesting that the ligand-binding activity of ClfA can be effectively neutralized through vaccination...
  13. pmc High Resolution Mapping of Bactericidal Monoclonal Antibody Binding Epitopes on Staphylococcus aureus Antigen MntC
    Alexey V Gribenko
    Pfizer Vaccine Research and Development, Pearl River, New York, United States of America
    PLoS Pathog 12:e1005908. 2016
    ..aureus infection by preventing the capture and transport of Mn2+, a key element that the pathogen uses to evade host immunity...
  14. doi request reprint Vaccine review: "Staphyloccocus aureus vaccines: problems and prospects"
    Kathrin U Jansen
    Pfizer Inc, 401 N Middletown Road, Pearl River, NY 10965, USA
    Vaccine 31:2723-30. 2013
    ..This review summarizes the potential underlying reasons why these two approaches may have failed, and proposes avenues that may provide successful vaccine approaches to prevent S. aureus disease in the future...
  15. doi request reprint Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide
    Lisa K McNeil
    Wyeth Research, 401 N Middletown Rd, Pearl River, NY 10965, United States
    Vaccine 27:3417-21. 2009
    ..The data presented in this paper demonstrates that Cap B does not interfere with the binding of antibodies to LP2086 expressed on the outer membrane of MnB clinical isolates...
  16. doi request reprint Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection
    Ingrid L Scully
    Pfizer Vaccine Research and Development, Pearl River, NY 10965, USA
    Vaccine 33:5452-7. 2015
    ....
  17. ncbi request reprint Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention
    Gustavo H Dayan
    a Pfizer Vaccine Research and Development, Pearl River, NY, USA
    Expert Rev Vaccines 15:1373-1392. 2016
    ..Prevention using a prophylactic vaccine would complement these processes, having the potential to bring additional, significant progress toward decreasing invasive disease due to S. aureus...
  18. doi request reprint Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine
    Luke R Green
    Pfizer Vaccine Research and Development Unit, 401 North Middletown Road, Pearl River, NY, USA
    Methods Mol Biol 1403:445-69. 2016
    ..Phase 3 clinical trials were carried out in the target populations to provide the clinical confirmation of safety and efficacy required for vaccine licensure. ..
  19. doi request reprint SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies
    Elizabeth Begier
    Pfizer Vaccine Clinical Research and Development, Pearl River, NY, USA Electronic address
    Vaccine . 2017
    ..This Phase 1 study aimed to confirm the safety and immunogenicity of SA4Ag produced by the final manufacturing process before efficacy study initiation in a surgical population...
  20. doi request reprint Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis
    Ellen Murphy
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    J Infect Dis 200:379-89. 2009
    ..We report an extensive survey and phylogenetic analysis of the diversity of fhbp genes and predicted protein sequences in invasive clinical isolates obtained in the period 2000-2006...
  21. doi request reprint Immunofluorescence microscopy for the detection of surface antigens in methicillin-resistant Staphylococcus aureus (MRSA)
    Yekaterina Timofeyeva
    Pfizer Vaccine Research, Pearl River, NY, USA
    Methods Mol Biol 1085:85-95. 2014
    ..Here, we apply the method to follow antigen expression on the surface of MRSA cells over time in in vivo infection models. ..
  22. doi request reprint Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines
    Jane Broughan
    Pfizer Vaccine Research, 401 N Middletown Road, Pearl River, NY 10965, USA
    Expert Rev Vaccines 10:695-708. 2011
    ..The composition and the early clinical results from the evaluation of these vaccines are discussed in this article...
  23. pmc Meningococcal serogroup B vaccines: Estimating breadth of coverage
    Robert G K Donald
    a Pfizer Vaccine Research and Development, Pearl River, NY, USA
    Hum Vaccin Immunother . 2016
    ..This review describes the rigorous approach used to assess broad coverage of bivalent rLP2086. Alternative nonfunctional assays proposed for assessing vaccine coverage are also discussed...
  24. doi request reprint Three-dimensional structure and biophysical characterization of Staphylococcus aureus cell surface antigen-manganese transporter MntC
    Alexey Gribenko
    Pfizer Vaccine Research, 401 North Middletown Road, Pearl River, NY 10965, USA
    J Mol Biol 425:3429-45. 2013
    ..Therefore, it is unlikely that antibody binding to this antigen will be affected by the occupancy of the metal-binding site by Mn²⁺...
  25. pmc Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines
    Eduardo Rojas
    Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America
    PLoS ONE 10:e0132140. 2015
    ..These rt-PCR assays provide a comprehensive means to identify and genogroup N. meningitidis in carriage studies used to guide vaccination strategies and to assess the impact of novel fHbp containing vaccines on meningococcal carriage. ..
  26. doi request reprint Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in Australia
    Helen S Marshall
    From the Vaccinology and Immunology Research Trials Unit, Women s and Children s Hospital, School of Paediatrics and Reproductive Health, Robinson Research Institute, University of Adelaide, North Adelaide, South Australia, Australia School of Paediatrics and Child Health, University of Western Australia, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Subiaco, Western Australia, Australia Queensland Paediatric Infectious Diseases Laboratory, Queensland Children s Medical Research Institute, Royal Children s Hospital, University of Queensland, Herston, Brisbane, Queensland, Australia National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children s Hospital at Westmead, Westmead, Marie Bashir Institute, The University of Sydney, Sydney, New South Wales, Australia Department of Paediatrics and Child Health, ANU Medical School, The Canberra Hospital, Canberra, Australian Capital Territory, Australia and Pfizer Vaccine Research, Pearl River, New York
    Pediatr Infect Dis J 34:831-8. 2015
    ..The aim of this study was to assess carriage rates and anti-streptococcal C5a peptidase (anti-SCP) IgG levels and identify epidemiologic factors related to carriage or seropositivity in Australian children...
  27. pmc Regulation of Staphylococcus aureus MntC expression and its role in response to oxidative stress
    Luke D Handke
    Pfizer Vaccine Research, Pearl River, New York, United States of America
    PLoS ONE 8:e77874. 2013
    ..Taken together, these results provide insight into the role of this antigen for the pathogen. ..